CytRx’s Arimoclomol To Be Administered In A Phase 2/Phase 3 Adaptive Clinical Trial In A Subset Of Patients With Familial ALS

February 24 2009

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced that a Phase 2/3 adaptive clinical trial has commenced to study its molecular chaperone regulator drug candidate arimoclomol in a subset of patients with the inherited or familial form of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

  • Donate
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...
  • Register Now!
  • Events

  • Register Now!
  • Navigation

    Show Sub-Pages | Hide Sub-Pages